HOMA-IR Calculator

What HOMA-IR is — and why it matters more than fasting glucose

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) was developed by David Matthews at Oxford in 1985 as a way to estimate insulin resistance from a single fasting blood draw. The math is simple: HOMA-IR = (fasting insulin × fasting glucose) ÷ 405 (mg/dL) or ÷ 22.5 (mmol/L). The reasoning behind the constant is steady-state pancreas modelling — at rest, the insulin needed to maintain a given fasting glucose is proportional to whole-body insulin resistance.

The clinical importance: fasting insulin rises years to decades before fasting glucose goes out of range. Joseph Kraft's seminal 1975 work (later expanded in his 2008 book) demonstrated that abnormal insulin patterns precede abnormal glucose by 5–15 years in most subjects who eventually develop type 2 diabetes. By the time fasting glucose hits 100 mg/dL (the prediabetes threshold), insulin resistance has typically been present for over a decade. HOMA-IR catches it earlier.

Reading the result — what the numbers mean

For non-diabetic adults, the widely-used clinical thresholds are: under 1.0 ideal, 1.0–1.4 healthy, 1.5–2.4 borderline or early insulin resistance, 2.5+ insulin-resistant, 4.0+ severely insulin-resistant. The cutoffs come from the Matthews 1985 paper, refined by Bonora 2003 and Geloneze 2010. Important caveat: HOMA-IR is less reliable in active T2D where beta-cell exhaustion confounds the math — by that stage you're measuring something different.

How to lower HOMA-IR

HOMA-IR is one of the most reversible metabolic markers — it drops fast with the right interventions. The Diabetes Prevention Program (NEJM 2002) and dozens of subsequent trials converge on a clear hierarchy:

• Lose 5–7% of body weight. The DPP found this reduced T2D incidence 58% over 3 years. HOMA-IR dropped 30–50% in successful losers.
• Exercise 150+ min/week, mixing aerobic and resistance. Independent of weight loss, this reduces HOMA-IR meaningfully.
• Reduce ultra-processed carbohydrates. Low-carb (50–130g/day) and Mediterranean-style diets both lower HOMA-IR — the common factor is reduced glycemic load, not low-carb specifically.
• Time-restricted eating (16:8 or similar). Multiple RCTs show 10–20% HOMA-IR reduction over 8–12 weeks even without weight loss.
• Resistance training, specifically. Trained muscle is a glucose sponge — adding 2–3 strength sessions/week reliably improves insulin sensitivity.
• Metformin (for those who qualify). Reduces HOMA-IR by 15–25% in non-diabetic insulin-resistant adults.

Why fasting insulin isn't on standard panels — and how to get it

Standard comprehensive metabolic panels don't include fasting insulin because diabetes diagnosis historically used glucose and A1C alone. But fasting insulin is one of the most informative routine markers for healthy and prediabetic adults. To get it: ask your primary care provider to order "fasting insulin" alongside your annual CMP and HbA1c. If your insurance won't cover it, direct-to-consumer labs (Quest, LabCorp through online ordering platforms) typically charge $15–40. Always measure with at least 8 hours of fasting — water only, no coffee.

Related tools

• A1C ↔ eAG Converter
• Glucose Unit Converter (mg/dL ↔ mmol/L)
• Glycemic Load Calculator
• BMI Calculator (Asia-Pacific cutoffs)

Frequently asked questions

What does HOMA-IR actually measure?

HOMA-IR is a steady-state model of fasting glucose-insulin dynamics, originally developed by David Matthews and colleagues at Oxford (Matthews et al., Diabetologia 1985). It estimates the basal rate at which the pancreas needs to produce insulin to maintain fasting glucose — higher values mean the body needs more insulin to keep glucose normal, which is the working definition of insulin resistance. It correlates moderately well (r ~0.5–0.7) with the gold-standard hyperinsulinemic-euglycemic clamp test in non-diabetic populations, much less well in T2D where pancreatic beta-cell function is the dominant variable.

What's a normal HOMA-IR value?

The original Matthews 1985 paper proposed <1.0 as ideal and 2.7 as a research-grade cutoff for insulin resistance in non-diabetic adults. Subsequent population studies have shown wide variation by ethnicity, BMI, and age. The 2003 Bonora cohort proposed 2.5 as the practical clinical cutoff. The 2010 Geloneze meta-analysis suggested 2.5–2.8 for white European populations and 1.8–2.0 for East Asian populations who develop insulin resistance at lower BMIs. Most clinicians use <1.5 as healthy, 1.5–2.4 as borderline, and ≥2.5 as insulin-resistant.

Why isn't fasting insulin on a standard blood panel?

Historically because diabetes was diagnosed by glucose alone, and fasting insulin doesn't change the standard T2D diagnosis. But fasting insulin rises 5–15 years before fasting glucose becomes abnormal — making it the single most useful early marker of metabolic dysfunction. Joseph Kraft's 1975 work and Jason Fung's more recent advocacy have pushed it into clinical use. Most US labs will run it if you specifically request it; it's typically $15–40 out of pocket if not covered. Order it alongside an HbA1c and fasting glucose to compute HOMA-IR.

Can HOMA-IR improve, and how fast?

Yes — HOMA-IR is highly responsive to lifestyle change. The Diabetes Prevention Program (DPP, NEJM 2002) and subsequent lifestyle intervention studies show that 5–7% weight loss combined with 150 minutes/week of moderate exercise can reduce HOMA-IR by 30–50% within 12–24 weeks. Low-carbohydrate and Mediterranean diets reliably reduce HOMA-IR. Resistance training plus modest weight loss can normalise HOMA-IR even without major weight change. Time-restricted eating (16:8 or similar) reduces HOMA-IR in most studies. Metformin reduces HOMA-IR by 15–25% in non-diabetic insulin-resistant adults.

How is HOMA-IR different from HOMA-B and QUICKI?

HOMA-IR measures insulin resistance. HOMA-B (or HOMA-%B) measures pancreatic beta-cell function from the same two inputs but with a different formula. QUICKI (Quantitative Insulin Sensitivity Check Index) is a log-transformed version of HOMA-IR that correlates slightly better with clamp-measured insulin sensitivity in obese subjects. For everyday clinical use HOMA-IR is the standard. HOMA-B is informative when beta-cell exhaustion is suspected (e.g., long-standing T2D, LADA). QUICKI is mostly used in research papers.